2. Academic Validation
  3. Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

  • J Med Chem. 2016 Sep 22;59(18):8233-62. doi: 10.1021/acs.jmedchem.6b00157.
Eugene Guorong Yang 1,  Nurulhuda Mustafa 2,  Eng Chong Tan 3,  Anders Poulsen 4 5,  Pondy Murugappan Ramanujulu 1 6,  Wee Joo Chng 2 7 8,  Jeffrey J Y Yen 3,  Brian W Dymock 1
Affiliations

Affiliations

  • 1 Department of Pharmacy, National University of Singapore , 18 Science Drive 4, Singapore 117543.
  • 2 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore , 1E Kent Ridge Road, NUHS Tower Block Level 10, Singapore 119228.
  • 3 Institute of Biomedical Sciences, Academia Sinica , Taipei 11529, Taiwan.
  • 4 Experimental Therapeutics Centre , 31 Biopolis Way, 03-01 Nanos, Singapore 138669.
  • 5 Department of Chemistry, National University of Singapore , 3 Science Drive 3, Singapore 117543.
  • 6 Life Sciences Institute, National University of Singapore , Centre for Life Sciences, Level 5, 28 Medical Drive, Singapore 117456.
  • 7 Cancer Science Institute, Singapore, National University of Singapore , Singapore 117599.
  • 8 National University Cancer Institute of Singapore, National University Health System Singapore 119074.
PMID: 27541357 DOI: 10.1021/acs.jmedchem.6b00157
Abstract

Blockage of more than one oncoprotein or pathway is now a standard approach in modern Cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 Inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, 51, inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, submicromolar potent against HDACs 1, 8, and 11, and >50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of Apoptosis. This study provides new tool compounds for further exploration of dual JAK-HDAC pathway inhibiton achieved with a single molecule.

Figures
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验，部分功能也使用 Cookies 帮助我们更好地理解您的需求，为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问，请阅读我们的《隐私声明》。

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z